Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother. 1993;31:1–16.
CAS
PubMed
Google Scholar
Ehmann L, Simon P, Busse D, Petroff D, Dorn C, Huisinga W, et al. Risk of target non-attainment In obese compared to non-obese patients In Calculated linezolid therapy. Clin Microbiol Infect. 2020;26:1222–8.
Zeitlinger MA, Erovic BM, Sauermann R, Georgopoulos A, Müller M, Joukhadar C. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother. 2005;56:703–8.
CAS
PubMed
Google Scholar
EMA. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. 2017.
Google Scholar
Plock N, Kloft C. Microdialysis - theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1–24.
CAS
PubMed
Google Scholar
Dhanani J, Roberts JA, Chew M, Lipman J, Boots RJ, Paterson DL, et al. Antimicrobial chemotherapy and lung microdialysis: a review. Int J Antimicrob Agents. 2010;36:491–500.
CAS
PubMed
Google Scholar
Cano-Cebrián MJ, Zornoza T, Polache A, Granero L. Quantitative in vivo microdialysis in pharmacokinetic studies: some reminders. Curr Drug Metab. 2005;6:83–90.
PubMed
Google Scholar
Dorn C, Petroff D, Neumann N, Kratzer A, El-Najjar N, Dietrich A, et al. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. J Antimicrob Chemother. 2019;74:2335–40.
CAS
PubMed
Google Scholar
Kirbs C, Kluwe F, Drescher F, Lackner E, Matzneller P, Weiss J, et al. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Eur J Pharm Sci. 2019;131:218–29.
CAS
PubMed
Google Scholar
Hutschala D, Kinstner C, Skhirtladze K, Mayer-Helm BX, Zeitlinger M, Wisser W, et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Med. 2008;34:1827–34.
CAS
PubMed
Google Scholar
Brill MJE, Houwink API, Schmidt S, Van Dongen EPA, Hazebroek EJ, van Ramshorst B, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2013;69:715–23.
PubMed
Google Scholar
Tegeder I, Lötsch J, Kinzig-Schippers M, Sörgel F, Kelm GR, Meller ST, et al. Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen. Pharm Res. 2001;18:980–6.
CAS
PubMed
Google Scholar
Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, et al. Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther. 2007;81:659–68.
CAS
PubMed
Google Scholar
Tunblad K, Hammarlund-Udenaes M, Jonsson EN. An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res. 2004;21:1698–707.
CAS
PubMed
Google Scholar
Ullah S, Matzneller P, Zeitlinger M, Fuhr U, Taubert M. A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. Naunyn Schmiedeberg's Arch Pharmacol. 2019;392:1097–106.
CAS
Google Scholar
Minichmayr IK, Schaeftlein A, Kuti JL, Zeitlinger M, Kloft C. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients. Clin Pharmacokinet. 2017;56:617–33.
CAS
PubMed
Google Scholar
Blandeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 1999;21:3–40.
Google Scholar
Barth AB. Levofloxacin dose optimization for multidrug-resistant tuberculosis based on lung microdialysis in patients: University of Florida; 2014. https://ufdc.ufl.edu/UFE0047152 (
Lynch JP III, File TM Jr, Zhanel GG. Levofloxacin for the treatment of community-acquired pneumonia. Expert Rev Anti-Infect Ther. 2006;4:725–42.
CAS
PubMed
Google Scholar
Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti-Infect Ther. 2010;8:505–14.
CAS
PubMed
Google Scholar
Brinkmann A, Röhr AC, Frey OR, Krüger WA, Brenner T, Richter DC, et al. S2k-Leitlinie der PEG zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Anaesthesist. 2018;67:936–49.
CAS
PubMed
Google Scholar
Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.
CAS
PubMed
Google Scholar
Scaglione F, Mouton JW, Mattina R, Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother. 2003;47:2749–55.
CAS
PubMed
PubMed Central
Google Scholar
Bellmann R, Kuchling G, Dehghanyar P, Zeitlinger M, Minar E, Mayer BX, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol. 2004;57:563–8.
CAS
PubMed
PubMed Central
Google Scholar
Zeitlinger MA, Traunmüller F, Abrahim A, Müller MR, Erdogan Z, Müller M, et al. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int J Antimicrob Agents. 2007;29:44–50.
CAS
PubMed
Google Scholar
Zeitlinger MA, Dehghanyar P, Mayer BX, Schenk BS, Neckel U, Heinz G, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis 2003;47:3548–3553.
Neckel U, Joukhadar C, Frossard M, Jäger W, Müller M, Mayer BX. Siumltaneous determination of levoflocaxin and ciprofloxacin in microdialysates and plasma by high- performance liquid chromatography. Anal Chim Acta. 2002;463:199–206.
CAS
Google Scholar
Lindbom L, Pihlgren P, Jonsson N. PsN-toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79:241–57.
Google Scholar
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
CAS
Google Scholar
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight 2005;44:1051–1065.
Ette EI, Sun H, Ludden TM. Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol. 1998;38:417–23.
CAS
PubMed
Google Scholar
Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. New York: Springer; 2011.
Google Scholar
S Bradley J, Merali Garonzik S, Forrest A, M Bhavnani S. Pharmacokinetics, pharmacodynamics, and monte carlo simulation selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010;29:1043–6.
Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793–7.
CAS
PubMed
PubMed Central
Google Scholar
European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, Version 9.0, 2019. n.d. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.0_Breakpoint_Tables.pdf.
Carral N, Lukas JC, Oteo I, Suarez E. Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. Int J Antimicrob Agents. 2015;45:79–83.
CAS
PubMed
Google Scholar
Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between Fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590–7.
CAS
PubMed
Google Scholar
Ghimire S, van’t Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WCM, van Soolingen D, Kosterink JGW, et al. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. J Antimicrob Chemother. 2016;71:2691–703.
PubMed
Google Scholar
Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, Gatifloxacin, and Moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agent Chemother. 2008;52:852–7.
CAS
Google Scholar
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.
CAS
PubMed
Google Scholar
Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006;28:62–8.
CAS
PubMed
Google Scholar
Scheerans C, Heinig R, Mueck W. Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms. Biopharm Drug Dispos. 2015;36:93–103.
CAS
PubMed
PubMed Central
Google Scholar
Tomas A, Stilinović N, Sabo A, Tomić Z. Use of microdialysis for the assessment of fluoroquinolone pharmacokinetics in the clinical practice. Eur J Pharm Sci. 2019;131:230–42.
CAS
PubMed
Google Scholar
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101–19.
CAS
PubMed
Google Scholar
Chien SC, Chow AT, Rogge MC, Williams RR, Hendrix CW. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agent Chemother. 1997;41:1765–9.
CAS
Google Scholar
Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros. 2006;5:153–7.
CAS
PubMed
Google Scholar
Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agent Chemother. 1998;42:1098–104.
CAS
Google Scholar
Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of Meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83:452–9.
CAS
PubMed
Google Scholar
Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013;57:5679–83.
CAS
PubMed
PubMed Central
Google Scholar